US5965088A - Method for providing rapid disinfection of contact lenses - Google Patents
Method for providing rapid disinfection of contact lenses Download PDFInfo
- Publication number
- US5965088A US5965088A US08/956,514 US95651497A US5965088A US 5965088 A US5965088 A US 5965088A US 95651497 A US95651497 A US 95651497A US 5965088 A US5965088 A US 5965088A
- Authority
- US
- United States
- Prior art keywords
- carbon atoms
- group
- minutes
- solution
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000004659 sterilization and disinfection Methods 0.000 title description 28
- 229940123208 Biguanide Drugs 0.000 claims abstract description 65
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 55
- 230000000249 desinfective effect Effects 0.000 claims abstract description 41
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000002791 soaking Methods 0.000 claims abstract description 30
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 16
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 238000004140 cleaning Methods 0.000 claims abstract description 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 7
- -1 alkoxyalkyl ether Chemical compound 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 37
- 150000004283 biguanides Chemical class 0.000 claims description 28
- 239000004094 surface-active agent Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 23
- 239000002736 nonionic surfactant Substances 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 11
- 239000012458 free base Substances 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 239000006172 buffering agent Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 125000005515 organic divalent group Chemical group 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 239000012929 tonicity agent Substances 0.000 claims description 2
- 101100177155 Arabidopsis thaliana HAC1 gene Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 145
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 47
- 229950010221 alexidine Drugs 0.000 description 47
- 238000012360 testing method Methods 0.000 description 46
- 150000001875 compounds Chemical class 0.000 description 23
- 239000000047 product Substances 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 241000607715 Serratia marcescens Species 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 14
- 230000000845 anti-microbial effect Effects 0.000 description 14
- 239000000645 desinfectant Substances 0.000 description 13
- 244000005700 microbiome Species 0.000 description 13
- 239000002054 inoculum Substances 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 229920002413 Polyhexanide Polymers 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012956 testing procedure Methods 0.000 description 8
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 7
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 7
- 241000607720 Serratia Species 0.000 description 7
- 229960003260 chlorhexidine Drugs 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 6
- 239000002280 amphoteric surfactant Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229910021538 borax Inorganic materials 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 235000010338 boric acid Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000882 contact lens solution Substances 0.000 description 6
- 150000004985 diamines Chemical class 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 235000010339 sodium tetraborate Nutrition 0.000 description 6
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 6
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 5
- 241000223218 Fusarium Species 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000589516 Pseudomonas Species 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 5
- 229960001484 edetic acid Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- 230000002070 germicidal effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003641 microbiacidal effect Effects 0.000 description 4
- 229920001987 poloxamine Polymers 0.000 description 4
- IXBPPZBJIFNGJJ-UHFFFAOYSA-N sodium;cyanoiminomethylideneazanide Chemical compound [Na+].N#C[N-]C#N IXBPPZBJIFNGJJ-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000427940 Fusarium solani Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 2
- CXCSZVYZVSDARW-UHFFFAOYSA-N 1,2-dicyanoguanidine Chemical compound N#CNC(N)=NC#N CXCSZVYZVSDARW-UHFFFAOYSA-N 0.000 description 2
- BGPJLYIFDLICMR-UHFFFAOYSA-N 1,4,2,3-dioxadithiolan-5-one Chemical compound O=C1OSSO1 BGPJLYIFDLICMR-UHFFFAOYSA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 238000004617 QSAR study Methods 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 229920002359 Tetronic® Polymers 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000004287 bisbiguanides Chemical class 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005702 oxyalkylene group Chemical group 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012449 sabouraud dextrose agar Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- IPVTWNBWVXXRLE-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-ethylhexyl)guanidine Chemical compound CCCCC(CC)CNC(=N)NC(N)=N IPVTWNBWVXXRLE-UHFFFAOYSA-N 0.000 description 1
- UBBHRFLEDZWRNR-UHFFFAOYSA-N 1-(diaminomethylidene)-2-propan-2-ylguanidine Chemical compound CC(C)N=C(N)N=C(N)N UBBHRFLEDZWRNR-UHFFFAOYSA-N 0.000 description 1
- TXTFYBKWONUOHK-UHFFFAOYSA-N 1-[6-[carbamimidoyl(cyano)amino]hexyl]-1-cyanoguanidine Chemical compound NC(=N)N(C#N)CCCCCCN(C#N)C(N)=N TXTFYBKWONUOHK-UHFFFAOYSA-N 0.000 description 1
- HRXRWSJLSJCCRZ-UHFFFAOYSA-N 1-[n'-[6-[[amino-[(n'-heptylcarbamimidoyl)amino]methylidene]amino]hexyl]carbamimidoyl]-2-heptylguanidine;dihydrochloride Chemical compound Cl.Cl.CCCCCCCN=C(N)NC(N)=NCCCCCCN=C(N)NC(N)=NCCCCCCC HRXRWSJLSJCCRZ-UHFFFAOYSA-N 0.000 description 1
- LQDGBMHYWHIHBD-UHFFFAOYSA-N 1-[n'-[6-[[amino-[(n'-hexylcarbamimidoyl)amino]methylidene]amino]hexyl]carbamimidoyl]-2-hexylguanidine;dihydrochloride Chemical compound Cl.Cl.CCCCCCN=C(N)NC(N)=NCCCCCCN=C(N)NC(N)=NCCCCCC LQDGBMHYWHIHBD-UHFFFAOYSA-N 0.000 description 1
- DPXOBJJJIQLMEO-UHFFFAOYSA-N 1-[n'-[6-[[amino-[(n'-octylcarbamimidoyl)amino]methylidene]amino]hexyl]carbamimidoyl]-2-octylguanidine;dihydrochloride Chemical compound Cl.Cl.CCCCCCCCN=C(N)NC(N)=NCCCCCCN=C(N)NC(N)=NCCCCCCCC DPXOBJJJIQLMEO-UHFFFAOYSA-N 0.000 description 1
- BRJJFBHTDVWTCJ-UHFFFAOYSA-N 1-[n'-[6-[[amino-[[n'-(2-ethylhexyl)carbamimidoyl]amino]methylidene]amino]hexyl]carbamimidoyl]-2-(2-ethylhexyl)guanidine;dihydrochloride Chemical compound Cl.Cl.CCCCC(CC)CN=C(N)NC(N)=NCCCCCCN=C(N)NC(N)=NCC(CC)CCCC BRJJFBHTDVWTCJ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- GJWHXWMUGWZNTO-UHFFFAOYSA-N 2,2-dimethylpropane Chemical compound [CH2]C(C)(C)C GJWHXWMUGWZNTO-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- YXZZOMVBHPCKMM-UHFFFAOYSA-N 2-[6-[[amino-(cyanoamino)methylidene]amino]hexyl]-1-cyanoguanidine Chemical compound N#CNC(N)=NCCCCCCN=C(N)NC#N YXZZOMVBHPCKMM-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- LTHNHFOGQMKPOV-UHFFFAOYSA-N 2-ethylhexan-1-amine Chemical compound CCCCC(CC)CN LTHNHFOGQMKPOV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004135 2-norbornyl group Chemical group [H]C1([H])C([H])([H])C2([H])C([H])([H])C1([H])C([H])([H])C2([H])* 0.000 description 1
- RTTNMYWPMMYGIS-UHFFFAOYSA-N 3-(diaminomethylidene)-1,1-diethylguanidine Chemical compound CCN(CC)C(=N)NC(N)=N RTTNMYWPMMYGIS-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- HEAQOCBITATQEW-UHFFFAOYSA-N 5-amino-4-fluoro-2-methylphenol Chemical compound CC1=CC(F)=C(N)C=C1O HEAQOCBITATQEW-UHFFFAOYSA-N 0.000 description 1
- WGFUAJNREFNKPN-UHFFFAOYSA-N 5-chlorothiadiazole-4-carboxamide Chemical compound NC(=O)C=1N=NSC=1Cl WGFUAJNREFNKPN-UHFFFAOYSA-N 0.000 description 1
- XMVQMBLTFKAIOX-UHFFFAOYSA-N 6-azaniumylhexylazanium;dichloride Chemical compound [Cl-].[Cl-].[NH3+]CCCCCC[NH3+] XMVQMBLTFKAIOX-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910021204 NaH2 PO4 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010061137 Ocular toxicity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- QWJNFFYFEKXZBF-UHFFFAOYSA-N cyanocyanamide Chemical compound N#CNC#N QWJNFFYFEKXZBF-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- BORBLDJNKYHVJP-FXBDTBDDSA-N dolichodial Chemical compound C[C@H]1CC[C@H](C(=C)C=O)[C@@H]1C=O BORBLDJNKYHVJP-FXBDTBDDSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZQOHAQBXINVHHC-UHFFFAOYSA-N hex-2-enedinitrile Chemical compound N#CCCC=CC#N ZQOHAQBXINVHHC-UHFFFAOYSA-N 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- TWRQCVNFACGORI-UHFFFAOYSA-N hexane;dihydrochloride Chemical compound Cl.Cl.CCCCCC TWRQCVNFACGORI-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 231100000327 ocular toxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940093424 polyaminopropyl biguanide Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/141—Biguanides, e.g. chlorhexidine
- A61L12/142—Polymeric biguanides
Definitions
- This invention relates to new and improved methods for disinfecting contact lenses with ophthalmically safe disinfecting solutions comprising certain bis(biguanides), such that increased microbiocidal efficacy of the solution allows more rapid disinfecting regimens for treating contact lenses.
- contact lenses in wide use fall into two categories: (1) hard lenses formed from materials prepared by polymerization of acrylic esters, such as polymethyl methacrylate (PMMA), and the newer rigid gas permeable (RGP) lenses formed from silicone acrylates and fluorosilicone methacrylates and (2) gel, hydrogel or soft type lenses made of polymerized hydrophilic or hydrophobic monomers, such as 2-hydroxyethyl methacrylate (HEMA).
- PMMA polymethyl methacrylate
- RGP newer rigid gas permeable
- gel, hydrogel or soft type lenses made of polymerized hydrophilic or hydrophobic monomers, such as 2-hydroxyethyl methacrylate (HEMA).
- HEMA 2-hydroxyethyl methacrylate
- the hard acrylic type contact lenses are characterized by low water vapor diffusion constants, resistance to the effects of light, oxygen and hydrolysis and absorb only minor amounts of aqueous fluids. Because of the durability of hard contact lenses, coupled with their tendency not to absorb appreciable amounts of water,
- soft type contact lenses and certain of the newer rigid gas permeable contact lenses have a tendency to bind and concentrate significantly more fluids, environmental pollutants, water impurities, as well as antimicrobial agents and other active ingredients commonly found in lens care solutions.
- the low levels of the ingredients in lens care solutions do not lead to eye tissue irritation when used properly.
- some disinfecting agents and preservatives tend to build up on lens surfaces and may become concentrated to potentially hazardous levels, such that when released could cause corneal inflammation and other eye tissue irritation.
- the antimicrobial activity of the chlorhexidine may be diminished when used with certain amphoteric surfactants. Furthermore, it was reported that if not used in proper ratio, the surfactant and disinfectant will precipitate unless a non-ionic type surfactant is also employed.
- U.S. Pat. No. 4,361,548 discloses a contact lens disinfectant and preservative containing dilute aqueous solutions of a polymer; namely, polydimethyldiallylammonium chloride (DMDAAC) having molecular weights ranging from about 10,000 to 1,000,000. Amounts of DMDAAC homopolymer as low as 0.00001 percent by weight may be employed when an enhancer, such as thimerosal, sorbic acid or phenylmercuric salt is used therewith. Although lens binding and concomitant eye tissue irritation with DMDAAC were reduced, it was found in some users to be above desirable clinical levels.
- DMDAAC polydimethyldiallylammonium chloride
- U.S. Pat. No. 4,758,595 to Ogunbiyi et al. disclosed that a contact-lens solution containing a polyguanide biguanide (PAPB) has enhanced efficacy when combined with a borate buffer.
- PAPB polyguanide biguanide
- Such solutions are compatible with both hard and soft type lenses, and are adaptable for use with virtually any of the commonly known disinfecting techniques, including "cold" soaking under ambient temperature conditions, as well as with high temperature disinfecting methods. These disinfecting and preservative solutions are especially noteworthy for their broad spectrum of bactericidal and fungicidal activity at low concentrations coupled with very low toxicity when used with soft type contact lenses.
- Ogunbiyi et al. stated that biguanide polymers in the higher molecular weight ranges usually demonstrate lower toxicity levels than corresponding lower molecular weight materials.
- compositions containing PAPB and borate, or other non-phosphate buffers have been commercialized in various products, but at levels of about 1.0 ppm or less. It is generally desirable to provide the lowest level of a bactericide possible, while maintaining the desirable level of disinfection efficacy, in order to provide a generous margin for safety and comfort.
- contact-lens solutions containing PAPB require a regimen for the use of the product that requires a minimum of four hours soaking time. Obviously, such a soaking requirement is consistent with overnight disinfection and soaking of contact-lens, as is customarily done on a daily basis by contact-lens wearers. However, a contact-lens wearer may have occasion to remove his or her contact lenses for a shorter period of time, for example, while swimming, reading or any other activity where eyeglasses may be preferable for a particular task. Some people may wear eyeglasses for part of the day, for example, during certain work activities and may wear contact lenses for part of the day, for example, during certain social occasions.
- Removal of lenses at unscheduled times during the day may also occur through the need to remove environmental debris from the lens or may occur thru accidental lens removal, e.g., on occasion by blinking.
- a contact lens is installed in the eye a plurality of times during a single day, a four-hour soak may be neither practical nor convenient.
- reinsertion of lenses that are not properly disinfected may occur.
- a disinfecting solution that reduces the minimum period of soaking substantially below four hours would, therefore, be desirable.
- U.S. Pat. Nos. 5,411,597 and 5,411,598 to Tsao et al. disclose a contact-lens solution that is designed to disinfect a lens in a relatively short period of time.
- Such a solution comprises a high concentration of an alkylene glycol and an alkanol.
- a disadvantage of such a solution is that it is too toxic for contact with the human eye and, accordingly, must be rinsed from the contact lens before inserting the contact lens in the eye.
- the present invention is directed to method of disinfecting contact lenses with an ophthalmically safe disinfecting solution for contact lenses, which solution comprises about 2.0 to about 8.0 ppm of the hydrochloride salt of a bis(biguanide), or a corresponding concentration of the same bis(biguanide) in the form of the free base or a different water-soluble salt, which bis(biguanide) has the following general formula: ##STR2## wherein R 1 and R 4 are independently selected from the group consisting of branched or unbranched alkyl having 4-12 carbon atoms, alkoxyalkyl or alkylsulfide radical having 4-12 carbon atoms, or cycloalkyl or cycloalkyl-alkyl radical having 5-12 carbon atoms; R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl having 1-12 carbon atoms, alkoxyalkyl having 1-12 carbon atoms, or cycloalkyl or cycloalkyl-alkyl having 5-12 carbon
- the solutions used in the present invention may also comprise an effective amount of a buffering agent, preferably in the amount of from about 0.01 to 5% by weight, an effective amount of a surfactant, preferably in an amount of about 0.01% to 5% by weight, and water in an amount of at least about 90% by weight.
- a buffering agent preferably in the amount of from about 0.01 to 5% by weight
- an effective amount of a surfactant preferably in an amount of about 0.01% to 5% by weight
- water in an amount of at least about 90% by weight.
- the surfactant is a neutral or non-ionic surfactant.
- the invention comprises soaking the lens for a period of not more than 75 minutes in an aqueous solution comprising a microbiocidally effective amount, within the range of from about 2.0 to about 8.0 ppm, preferably 2.0 to 6.0 ppm of a bis(biguanide) of Formula (I) above, in the form of the dihydrochloride salt or a corresponding molar amount of another salt or its free base, in combination with an effective amount of at least one buffering agent, at least one tonicity agent, and at least one surfactant, and then directly placing the treated lens on an eye.
- the minimum soaking period ranges from about 10 to about 60 minutes.
- the present invention is directed to a composition, in the form of an aqueous solution containing a compound of Formula (I) above, and a method of using the solution for disinfecting and/or preserving contact lenses, especially soft contact lenses.
- the disinfecting solutions of the present invention are effective at low concentrations against a wide spectrum of microorganisms, including but not limited to Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Candida albicans, and Fusarium solani.
- a disinfecting solution is generally defined as a contact lens care product containing one or more active ingredients (for example, anti-microbial agents and/or preservatives) in sufficient concentrations to destroy harmful microorganisms on the surface of a contact lens within the recommended minimum soaking time.
- active ingredients for example, anti-microbial agents and/or preservatives
- the recommended minimum soaking time is included in the package instructions for use of the disinfecting solution.
- the present solution in combination with its container or bottle and packaging, including instructions for use, may be considered a novel and improved kit, package, or system for the care of contact lenses.
- soft lens is meant a lens having a proportion of hydrophilic repeat units such that the water content of the lens during use is at least 20% by weight.
- soft contact lens generally refers to those contact lenses which readily flex under small amounts of force.
- soft contact lenses are formulated from polymers having a certain proportion of repeat units derived from hydroxyethyl methacrylate and/or other hydrophilic monomers, typically crosslinked with a crosslinking agent.
- RGP rigid gas permeable lenses
- ophthalmically safe with respect to a contact-lens solution is meant that a contact lens treated with the solution is safe for direct placement on the eye without rinsing, that is, the solution is safe and sufficiently comfortable for daily contact with the eye via a contact lens.
- An ophthalmically safe solution has a tonicity and pH that is compatible with the eye and comprises materials, and amounts thereof, that are non-cytotoxic according to international ISO standards and U.S. FDA regulations.
- fecting solution a solution containing one or more microbiocidal compounds, that is effective for reducing or substantially eliminating the presence of an array of microorganisms present on a contact lens, which can be tested by challenging a solution or a contact lens after immersion in the solution with specified inoculums of such microorganisms.
- the term "disinfecting solution” as used herein does not exclude the possibility that the solution may also be useful for a preserving solution or that the disinfecting solution may additionally be useful for daily cleaning, rinsing and storage of contact lenses.
- a solution that is useful for cleaning, chemical disinfection, storing, and rinsing a contact lens is referred to herein as a "multi-purpose solution.”
- Such solutions may be part of a “multi-purpose solution system” or “multi-purpose solution package.”
- the procedure for using a multi-purpose solution, system or package is referred to as a "multi-functional disinfection regimen.”
- Multi-purpose solutions do not exclude the possibility that some wearers, for example, wearers particularly sensitive to chemical disinfectants or other chemical agents, may prefer to rinse or wet a contact lens with a another solution, for example, a sterile saline solution prior to insertion of the lens.
- multi-purpose solution also does not exclude the possibility of periodic cleaners not used on a daily basis or supplemental cleaners for removing proteins, for example enzyme cleaners, which are typically used on a weekly basis.
- cleaning is meant that the solution contains one or more active ingredients in sufficient concentrations to loosen and remove loosely held lens deposits and other contaminants on the surface of a contact lens, especially if used in conjunction with digital manipulation (for example, manual rubbing of the lens with a solution) or with an accessory device that agitates the solution in contact with the lens, for example, a mechanical cleaning aid.
- the bis(biguanide) germicides employed in the present solutions include compounds, and their water-soluble salts, having following formula: ##STR3## wherein R 1 and R 4 are independently selected (i.e., the same or different) from the group consisting of branched or unbranched alkyl having 4-12, preferably 6-10, carbon atoms, alkoxyalkyl (i.e., ether) or alkylsulfide (thioether or dialkylsufide) radical having 4-12, preferably 6-10, carbon atoms, or cycloalkyl or cycloalkyl-alkyl radical having 5-12, preferably 7-10, carbon atoms; R 2 and R 3 are independently selected from the group consisting of hydrogen, alkyl having 1-12, preferably 1-6, carbon atoms, alkoxyalkyl having 1-12, preferably 1-6, carbon atoms, or cycloalkyl or cycloalkyl-alkyl having 5-12, preferably 6
- cycloalkyl either in cycloalkyl or cycloalkyl-alkyl, is meant unsubstituted or substituted cycloalkyl, where the substituents are one or more alkyl, alkoxy (--OR), or alkylsulfide (--SR) groups having 1-6 carbon atoms.
- the biguanides of Formula (I) are suitably used in the total amount (with respect to the weight of the hydrochloride salt, often containing two hydrochlorides as in alexidine) of 2.5 to 8.0 ppm, preferably 2.5 to 6.0 ppm based on the total aqueous solution, or corresponding molar amounts when in the form of another salt or its free base. More preferably, the bis(biguanides) are used in the molar amount corresponding to 3.0 to 5.0 ppm, most preferably 3.5 to 4.5 ppm. of the hydrochloride salt.
- the above-indicated ppm ranges must be adjusted to obtain the corresponding ppm ranges such that the ranges are the same on a molar basis as for the dihydrochloride salt of the bis(biguanide).
- concentration of the bis(biguanide) in solution is generally directly related to its bactericidal efficacy.
- the corresponding weight of an equal molar amount or concentration of a different salt form of a bis(biguanide) or its free base can be readily calculated, for use in weighing out a suitable amount of the substance on hand whatever its form.
- the term "ppm” refers to "parts per million” and 1.0 ppm corresponds to 0.00010 weight percent. It is based on the total weight of the composition or, in this case, the total weight of the aqueous disinfecting solution.
- the amount of the bis(biguanide) or other components in a solution used in the present method refers to the amount formulated and introduced into the solution at the time the solution is made. Over time (for example, over a storage period of 18 months), the assayed amount of a bis(biguanide) in solution may decrease. For various reasons, however, the assayed amount may not be a good indicator of the remaining efficacy of the solution and any such decrease over time is taken into account when initially formulating a product.
- the bis(biguanide) compounds have the following formula: ##STR4## or their water-soluble salt form, wherein R 1 and R 4 are independently selected from the group consisting of branched or unbranched alkyl, alkoxyalkyl (i.e., ether) or alkylsulfide (thioether) radical, and n is 5 to 7.
- R 1 and R 4 in Formulas (I) or (II) above may be, for example, an n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, octyl, 2-ethylhexyl, dodecyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl or cyclohexylmethyl radical.
- 2-ethylhexyl (alexidine), 1,5-dimethylhexyl, 1-methylhexyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, cyclohexylmethyl, 2-norbornyl, propyloxyoctyl, and propyloxybutyl.
- R 2 and R 3 in Formula (I) above may be, for example, a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, octyl, 2-ethylhexyl, dodecyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylmethyl or cyclohexylmethyl radical.
- R 2 and R 3 is an alkoxyalkyl radical, it may be, for example, a 2-methoxyethyl.
- Each of R 6 and R 7 in Formula I may be, for example, a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, or neopentyl radical.
- Preferred A groups in Formula (I) include hexamethylene and a divalent hexamethylene interrupted with a divalent radical derived from 1,4-diaza-cyclohexane in which the nitrogen atoms are connected to alkylene groups having 1 to 4 carbon atoms, for example, resulting from the starting material N,N'-(2-aminoethyl)-1,4 piperadine or the like.
- the acid-addition salts of the invention may be derived from an inorganic or organic acid. In most circumstances it is preferable that the salts be derived from an acid which affords an anion which is suitable for human usage, for example a pharmaceutically-acceptable anion.
- acids are hydrochloric, hydrobromic, phosphoric, sulphuric, acetic, D-gluconic, 2-pyrrolidino-5-carboxylic, methanesulphonic, carbonic, lactic and glutamic acids.
- the bis(biguanides) of Formula (I) preferably have relatively hydrophobic end groups.
- the Log P of the compounds is 5 to 10, preferably 6 to 8, wherein P is the partition coefficient of the free base, using the following equation, wherein ⁇ is the degree of ionization: ##EQU1##
- the compound is partitioned between a 0.05 M phosphate buffer (pH 11) saturated with octanol and octanol saturated with phosphate buffer after gentle shaking at room temperature (26° C.).
- the volume ratio of these two phases and the amount of sample are chosen so that the absorbance of the sample from the buffered layer after partitioning has a value between 0.2 and 0.9, using a 1-cm cell and buffer solution as a blank.
- the P value can be determined using the above formula. See “Quantitative Structure-Activity Relationships for Biguanides, Carbamidates, and Bisbiguanides as Inhibitors of Streptococcus mutans NO. 6715", Warner, V. and Lynch, D., J. Med. Chem, 1979, Vol. 22, no. 4 at 359, 365; and Albert, and Serjeant, E., “Determination of Ionization and Stability Constants," Butler and Tanner Ltd., London, England, 1962, both references hereby incorporated by reference.
- Examples of preferred bis(biguanide) compounds of this invention are 2-(decylthiomethyl)-pentane-1,5-bis(5-isopropylbiguanide), 2-(decylthio-methyi)pentane-1,5-bis(5,5-diethylbiguanide), and hexane-1,6-bis(2-ethylhexylbiguanide), the latter also known as alexidine or 1,1 '-hexamethylenebis(5-(2-ethylhexyl)-biguanide) dihydrochloride.
- bis(biguanides) include 1,1'-hexamethylenebis(5-heptyl-biguanide) dihydrochloride, 1,1'-hexamethylenebis(5-octyl-biguanide) dihydrochloride, and 1,1'-hexamethylenebis(5-hexyl-biguanide) dihydrochloride.
- the biguanide compounds of Formula (I) wherein R 6 and R 7 are each hydrogen may be made by reacting a bis-cyanoguanidine of the formula: ##STR5## with an amine R 1 R 2 NH, or with two different amines R 1 R 2 NH and R 3 R 4 NH, in the form of an acid addition salt thereof, wherein A, R 1 , R 2 , R 3 and R 4 have the meanings stated above, at a temperature of 100° C. to 170° C.
- a preferred amine salt is the hydrochloride. Most diamines are commercially available from a variety of sources.
- the reactants are heated together until the reaction is complete.
- the reaction proceeds fastest at higher temperatures, but if thermal stability is a problem, the reaction should be carried out at lower temperature for a longer period.
- the reactants are most conveniently melted together in the absence of a solvent, but if desired an inert solvent such as DMSO 2-methoxyethanol, 2-ethoxyethanol, nitrobenzene, sulpholane, isopropanol, n-butanol, ethylene glycol dimethyl ether or water, or a mixture of such solvents, may be used.
- the bis-cyanoguanidine of Formula (VI) may be manufactured from known starting materials such as hexamethylenedinitrile which is reduced, for example, with hydrogen and Raney nickel or with borane in dimethyl sulphide to the corresponding diamine of Formula (VIII), and the diamine in the form of an acid-addition salt, conveniently the dihydrochloride, is reacted with sodium dicyanamide or other suitable salt to form the required starting material of Formula (VI), as depicted below.
- M is a sodium, potassium, zinc or other suitable salt.
- the sodium salt is commercially available.
- the compounds of the present invention can also be made by reacting a diamine of Formula (VIII) in the form of an acid addition salt, with a cyanoguanidine of the formula: ##STR7## or with a cyanoguanidine of Formula (IX) and a cyanoguanidine of the formula: ##STR8## and wherein A, R 1 , R 2 , R 3 , R 4 , R 6 and R 7 have the meanings stated above, at a temperature of 100° to 170° C.
- a suitable salt of the diamine is, for example, the dihydrochloride.
- the reactants are heated together until the reaction is complete. The reaction proceeds fastest at higher temperature, but if thermal stability is a problem, the reaction should be carried out at lower temperature over a longer period. If a melt can be formed at those temperatures the reactants are conveniently melted together in the absence of a solvent. If not, or alternatively, the reactants are heated together in a suitable inert solvent, for example those mentioned above.
- the acid-addition salts of the invention are obtained by conventional means.
- cyanoguanidines of the Formulae (IX) and (X) wherein R 6 and R 7 are hydrogen may be obtained by reacting sodium dicyanamide with an appropriate amine R 1 R 2 NH or R 3 R 4 NH, in the form of an acid-addition salt, conveniently the dihydrochloride, in a suitable inert solvent.
- the cyanoguanidines of Formulae (IX) and (X) wherein R 6 and R 7 are other than hydrogen may be obtained by reacting a dialkyl (cyanoimido)dithio-carbonate, for example dimethyl (cyanoimido)dithio-carbonate, with appropriate amines R 1 R 2 NH and R 6 NH 2 or R 3 R 4 NH and R 7 NH 2 .
- alexidine is produced from the following sequence of reactions. ##STR9## Compound (XI) is hexamethylenediamine dihydrochloride (MW 189), Compound (XII) is sodium dicyanamide, Compound XIII is HMBDA, hexamethylene bis(cyanoguanido), Compound (XIV) is 2-ethyl-hexylamine hydrochloride (MW 165.7), Compound (XV) is alexidine dihydrochloride a.k.a. [1,6-bis-(2-ethylhexylbiguanido]hexane dihydrochloride a.k.a.
- hexane-1,6-bis(2-ethylhexyl biguanide) dihydrochloride This compound has a MW (molecular weight I g/mole) of 581.7 and empirical formula C 26 H 56 N 10 .2HCl.
- the Compound (XV) is commercially available from various sources, including Sigma Chemical Co. (St Louis, Mo.).
- a second disinfectant/germicide can be employed as a solution preservative, but it may also function to potentiate, compliment or broaden the spectrum of microbiocidal activity of Formula (I).
- Suitable complementary germicidal agents include, but are not limited to thimerosol, sorbic acid, alkyl triethanolamines, phenylmercuric salts, e.g.
- Suitable salts are soluble in water at ambient temperature to the extent of at least 0.5 weight percent. These salts include the gluconate, isethionate, (2-hydroxyethanesulfonate), formate, acetate, glutamate, succinanate, monodiglycollate, methanesulfonate, lactate, isobutyrate and glucoheptonate.
- potentiating or complementary disinfecting agents for use in the present invention also include certain quaternary ammonium compounds which possess a generally wide spectrum of bactericidal activity and wetting properties.
- Representative examples of the quaternary ammonium compounds are compositions comprised of balanced mixtures of n-alkyl dimethyl benzyl ammonium chlorides.
- Other examples include polymeric quaternary ammonium salts used in ophthalmic applications such as polyquaternium 1® (chemical registry number 75345-27-6) available from Onyx corporation.
- the bis(biguanides) defined above may be used in combination with lesser amounts of other bis(biguanides), for example chlorhexidine.
- Such compounds have been disclosed in greater detail in United Kingdom patent specification No. 705,838.
- the bis(biguanides) of the present invention may be used in combination with polymeric biguanides, and water-soluble salts thereof, having the following formula: ##STR10## wherein Z is an organic divalent bridging group which may be the same or different throughout the polymer, n is at least 3, preferably and X 1 and X 2 are independently selected from thegroups --NH 2 and ##STR11## In the above formula, n is preferably 5 to 20.
- One preferred group of water-soluble polymeric biguanides will have average molecular weights of at least 1,000 and more preferably will have average molecular weights from 1,000 to 50,000.
- Suitable water-soluble salts of the free bases include, but are not limited to hydrochloride, borate, acetate, gluconate, sulfonate, tartrate and citrate salts.
- the polymeric biguanides in combination with the bisbiguanides of the present invention, are effective in concentrations as low as 0.00001 weight percent (0.1 ppm). It has also been found that the bactericidal activity of the solutions may be enhanced or spectrum of activity broadened through the use of such polymeric biguanides. As a result, the total concentration of disinfectant of Formula (I) when used in combination with a polymeric biguanide of Formula (V) may be lowered further due to complimentary bactericidal activity, which is most desirable in achieving the lowest possible potential for lens binding, concentrating and eye tissue inflammation.
- polystyrene resin Most preferred are the polymeric hexamethylene biguanides (commercially available as the hydrochloride salt from Zeneca, Wilmington, DE under the trademark CosmocilTM CQ), their polymers and water-soluble salts being most preferred, referred to as polyaminopropyl biguanide (also sometimes referred to as PAPB or PHMB).
- polyhexamtheylene biguanide as used herein, is meant to encompass one or more biguanides having the following formula: ##STR12## wherein X 1 and X 2 are as defined above and n is from 1 to 500.
- the predominant compound falling within the above formula may have different X 1 and X 2 groups or the same groups, with lesser amounts of other compounds within the formula.
- Such compounds are known and are disclosed in U.S. Pat. No. 4,758,595 and British Patent 1,432,345, which patents are hereby incorporated herein by reference.
- the water-soluble salts are compounds where n has a value of 2 to 12, most preferably 3 to 8.
- the solutions used in the present invention may comprise at least one surfactant.
- Suitable surfactants can be either amphoteric, cationic, anionic, or nonionic which may be present (individually or in combination) in amounts up to 15 percent, preferably up to 5.0 percent by weight of the composition or solution.
- Preferred surfactants are amphoteric or nonionic surfactants, which when used impart cleaning and conditioning properties.
- the surfactant should be soluble in the lens care solution and non-irritating to eye tissues.
- Many nonionic surfactants comprise one or more chains or polymeric components having oxyalkylene (--O--R--) repeats units wherein R has 2 to 6 carbon atoms.
- Preferred non-ionic surfactants comprise block polymers of two or more different kinds of oxyalkylene repeat units, which ratio of different repeat units determined the HLB of the surfactant.
- Satisfactory non-ionic surfactants include polyethylene glycol esters of fatty acids, e.g. coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of higher alkanes (C 12 -C 18 ). Examples of the preferred class include polysorbate 20 (available under the trademark Tween 20), polyoxyethylene (23) lauryl ether (Brij® 35), polyoxyethyene (40) stearate (Myrj® 52), polyoxyethylene (25) propylene glycol stearate (Atlas® G 2612).
- Non-ionic surfactant in particular consisting of a poly(oxypropylene)-poly(oxyethylene) adduct of ethylene diamine having a molecular weight from about 7,500 to about 27,000 wherein at least 40 weight percent of said adduct is poly(oxyethylene) has been found to be particularly advantageous for use in cleaning and conditioning both soft and hard contact lenses when used in amounts from about 0.01 to about 15 weight percent.
- CTFA Cosmetic Ingredient Dictionary's adopted name for this group of surfactants is poloxamine. Such surfactants are available from BASF Wyandotte Corp., Wyandotte, Michigan, under the registered trademark "Tetronic".
- An analogous of series of surfactants, also suitable for use in the present invention, is the poloxamer series which is a poly(oxyethylene) poly(oxypropylene) block polymers available under the trademark "Pluronic" (commercially available form BASF).
- ionic as well as amphoteric and anionic surfactants suitable for in the invention can be readily ascertained, in view of the foregoing description, from McCutcheon's Detergents and Emulsifiers, North American Edition, McCutcheon Division, MC Publishing Co., Glen Rock, N.J. 07452 and the CTFA International Cosmetic Ingredient Handbook, Published by The Cosmetic, Toiletry, and Fragrance Association, Washington, D.C.
- Various non-surfactants may be added to enhance cleaning, for example, certain phosphonates such as Dequest® 2010 phosphonate.
- Amphoteric surfactants suitable for use in the present invention include materials of the type are offered commercially under the trade name "Miranol”. Another useful class of amphoteric surfactants may be exemplified by the following chemical structure are exemplified by cocoamidopropyl betaine commercially available under the tradename Amphoso® CA.
- surfactants when employed with a buffer enhancer will generally be present in an amount from 0.01 to 5.0 percent (w/w), preferably 1.0 to 5.0 percent
- the solutions used in the present invention for treating contact lenses are also adjusted with tonicity agents, preferably to approximate the osmotic pressure of normal lacrimal fluids which is equivalent to a 0.9 percent solution of sodium chloride or 2.5 percent of glycerol solution.
- the solutions can be made substantially isotonic with physiological saline used alone or in combination, otherwise if simply blended with sterile water and made hypotonic or made hypertonic the lenses will lose their desirable optical parameters.
- excess saline may result in the formation of a hypertonic solution which will cause stinging and eye irritation.
- the pH of solutions used in the present invention should be maintained within the range of 5.0 to 8.0, more preferably about 6.0 to 8.0, most preferably about 6.5 to 7.8, suitable buffers may be added, such as boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na 2 HPO 4 , NaH 2 PO 4 and KH 2 PO 4 ) and mixtures thereof Borate buffers are preferred, particularly for enhancing the efficacy of biguanides.
- buffers are used in amounts ranging from about 0.05 to 2.5 percent by weight, and preferably, from 0.1 to 1.5 percent.
- the disinfecting/preserving solutions of this invention preferably contain a borate or mixed phosphate buffer, containing one or more of boric acid, sodium borate, potassium tetraborate, potassium metaborate or mixtures of the same.
- Ethylene-diaminetetraacetic acid (EDTA) and its salts (disodium) are preferred examples. They are usually added in amounts ranging from about 0.01 to about 0.2 weight percent.
- Other suitable sequestering agents include gluconic acid, citric acid, tartaric acid and their salts, e.g. sodium salts.
- Aqueous solutions of the bis(biguanides) of Formula (I) are especially useful for soft contact lenses, with or without further additives. Nevertheless, the solutions of the present invention may be formulated into specific contact-lens care products, such as wetting solutions, soaking solutions, cleaning and conditioning solutions, as well as multi-purpose type lens care solutions. Various additives may make the solutions more acceptable to the user in terms of greater comfort. However, the additives must be non-toxic and compatible with contact lenses.
- water-soluble viscosity builders in the solutions of the present invention. Because of their demulcent effect, viscosity builders have a tendency to enhance the lens wearer's comfort by means of a film on the lens surface cushioning impact against the eye. Included among the water-soluble viscosity builders are the cellulose polymers like hydroxyethyl or hydroxypropyl cellulose, carboxymethyl cellulose and the like. Such viscosity builders may be employed in amounts ranging from about 0.01 to about 4.0 weight percent or less.
- the present solutions may also include optional demulcents.
- aqueous solutions according to the present invention can be effectively used in disinfecting contact lenses by any of the well recognized methods.
- the lenses may be treated at about room temperature.
- the lenses are then removed from the solution and may be rinsed with the same or a different solution, for example a preserved isotonic saline solution and then replaced on the eye.
- the lens is rubbed with a multi-purpose solution according to the present invention, followed by soaking for a total period of time that is within a range of 5 minutes to 75 minutes, prior to direct placement, corresponding to a minimum required (or recommended) soaking period that is a given time period in the same range.
- direct placement is herein meant that the solution is not diluted or rinsed off the lens with a different contact-lens solution prior to "insertion" or placement on the eye.
- the soaking time may be about 7.5 to about 60 minutes, more preferably may be about 10 minutes to about 45 minutes, most preferably may be about 10 minutes to about 30 minutes, with corresponding minimum recommended (or required) soaking periods not more than about 60 minutes, preferably not more than about 45 minutes, more preferably not more than about 30 minutes.
- a solution having a minimum soaking period of 10 minutes, requiring a soaking period of at least 10 minutes, is especially preferred for use by contact-lens wearers.
- This Example illustrates the preparation of 1,6-bis(cyanqguanidino)hexane, used, as a starting material for bis(biguanides) of the present invention.
- sodium dicyanamide NaC 2 N 3
- 1-butanol aqueous hydrochloric acid
- 23.60 g (0.204 mole) of 1,6-hexanediamine were added as well as 33.0 mL of conc. aqueous hydrochloric acid (0.400 mole).
- a milky white precipitate appeared immediately which was probably the amine hydrochloride.
- the mixture was then refluxed for 3.5 hr.
- the suspension was then cooled to room temperature and filtered.
- This Example illustrates the preparation of alexidine for use in the present invention.
- the compound 1,6-Bis(cyanoguanidino)hexan in the amount of 1.003 g (0.004498 moles) was placed into a flask. To this was added 1.474 mL (1.163 g; 0.008996 moles) of 2-ethylhexylamine. Then, 0.74 mL (0.008996 moles) of concentrated HCl was added. The mixture was heated in a flask to boil away the H 2 O. After the H 2 O was gone, the temperature of the melt had risen to 195° C. The temperature was decreased to 150-160° C. and maintained for 1 hour. The material was cooled to room temperature. The solid can be dissolved in hot water and allowed to crystallize.
- This Example illustrates the preparation of poly(hexamethylene biguanide), also referred to as PAPB or PHMB, for use in combination with bis(biguanides) in the present invention.
- PAPB poly(hexamethylene biguanide)
- PHMB poly(hexamethylene biguanide)
- This Example illustrates the preparation of an aqueous contact-lens disinfectant solution for use in the present invention.
- the solution is prepared by gradually heating 80 percent of the water to 80° C. while dissolving the disodium EDTA therein.
- the boric acid and sodium borate are added to the heated solution of disodium EDTA and dissolved.
- the sodium chloride is then added to the solution and dissolved, followed by the addition of surfactants.
- the solution is sterilized by autoclaving to 120° C. for 45 minute. After the solution is cooled to room temperature, the bis(biguanide) is added through a sterile filter, followed by the balance of distilled water.
- the solution is packaged in sterilized plastic containers.
- This Example illustrates the microbiocidal efficacy of solutions according to the present invention.
- the antimicrobial efficacy of each of various compositions for the chemical disinfection of contact lenses was evaluated.
- Microbial challenge inoculums were prepared using Pseudomonas aeruginosa (ATCC 9027), Staphylococcus aureus (ATCC 6538), Serratia marcescens (ATCC 13880), Candida albicans (ATCC 10231), and Fusarium solani (ATCC 36031).
- test organisms were cultured on appropriate agar and the cultures were harvested using sterile DPBST (Dulbecco's Phosphate Buffered Saline plus 0.05% w/v polysorbate 80) or a suitable diluent and transferred to a suitable vessel. Spore suspensions were filtered through sterile glass wool to remove hyphal fragments. Serratia marcescens, as appropriate, was filtered (eg., through a 1.2 ⁇ filter) to clarify the suspension. After harvesting, the suspension was centrifuged at no more than 5000 ⁇ g for a maximum of 30 minutes at 20-25° C. The supernatant was poured off and resuspended in DPBST or other suitable diluent.
- the suspension was centrifuged a second time, and resuspended in DPBST or other suitable diluent. All challenge bacterial and fungal cell suspensions were adjusted with DPBST or other suitable diluent to 1 ⁇ 10 7 -10 8 cfu/mL. The appropriate cell concentration may be estimated by measuring the turbidity of the suspension, for example using a spectrophotometer at a preselected wavelength, for example 490 nm. One tube was prepared containing a minimum of 10 mL of test solution per challenge organism.
- Each tube of the solution to be tested was inoculated with a suspension of the test organism sufficient to provide a final count of 1.0 ⁇ 10 5 -10 6 cfu/mL, the volume of the inoculum not exceeding 1% of the sample volume. Dispersion of the inoculum was ensured by vortexing the sample for at least 15 seconds.
- the inoculated product was stored at 10-25° C. Aliquots in the amount of 1.0 mL were taken of the inoculated product for determination of viable counts after certain time periods of disinfection.
- the time points for the bacteria were 25, 50, 75, and 100% of the minimum disinfection time.
- Yeast and mold were tested at an additional timepoint of at least 400% of the minimum disinfection time.
- the suspension was mixed well by vortexing vigorously for at least 5 second.
- the 1.0 mL aliquots removed at the specified time intervals were subjected to a suitable series of decimal dilutions in validated neutralizing media.
- the suspensions were mixed vigorously and incubated for a suitable period of time to allow for neutralization of the microbial agent.
- the viable count of organisms was determined in appropriate dilutions by preparation of triplicate plates of trypticase soy (TSA) agar for bacteria and Sabouraud dextrose agar (SDA) for mold and yeast.
- TSA trypticase soy
- SDA Sabouraud dextrose agar
- the bacterial recovery plates were incubated at 30-35° C. for 2-4 days.
- the yeast was incubated at 20-30° C.
- inoculum controls were made by dispersing an identical aliquot of the inoculum into a suitable diluent, for example DPBST, using the same volume of diluent used to suspend the organism as listed above. Following inoculation in a validated neutralizing broth and incubation for an appropriate period of time, the inoculum control must be between 1.0 ⁇ 10 5 -1.0 ⁇ 10 6 cfu/mL
- the solutions were evaluated based on the performance requirement referred to as the "Stand-Alone Procedure for Disinfecting Products" (hereafter the "stand-alone test") and is based on the Disinfection Efficacy Testing for contact lens care products under the Draft Premarket Notification (510(k)) Guidance Document For Contact Lens Care Products dated Apr. 1, 1996, prepared by the U.S. Food and Drug Administration, Division of Ophthalmic Devices. This performance requirement is comparable to current ISO standards for disinfection of contact lenses (revised 1995).
- the stand-alone test challenges a disinfecting product with a standard inoculum of a representative range of microorganisms and establishes the extent of viability loss at pre-determined time intervals comparable with those during which the product may be used.
- the primary criteria for a given disinfection period (corresponding to a potential minimum recommended disinfection period) is that the number of bacteria recovered per mL must be reduced by a mean value of not less than 3.0 logs within the given disinfection period.
- the number of mold and yeast recovered per mL must be reduced by a mean value of not less than 1.0 log within the minimum recommended disinfection time with no increase at four times the minimum recommended disinfection time.
- the secondary performance criteria exists which if passed qualifies the solution for the so-called "regimen test procedure" described in the FDA's Draft for Premarket Notification (510(k)) Guidance Document For Contact Lens Care Product, dated Apr.
- the regimen test challenges the proposed disinfection regimen (typically involving rubbing) with a standard inoculum of a representative range of microorganisms, in which test the inoculum is carried through the various stages of regimen by preliminary application to contact lenses.
- Example 4 shows the antimicrobial efficacy of the solution of Example 4 according to the present invention using the testing procedures described in Example 5 above, but formulated at a concentration of 4.0 ppm alexidine and at time intervals of 15 min, 30 min, 45 min, and 60 min, which would represent 25%, 50%, 75% and 100% of a one hour minimum recommended disinfection time.
- the solution had been aged for 19 months at 25° C. The results are shown in Table 3 below.
- the alexidine solution formulated at 4.0 ppm is able to pass a stand-alone test (with no rub or rinse) at the 30 minute time point, 45 time point and the 60 minute time point. With respect to Staphylococcus aureus the 15 minute time point failed.
- Example 4 shows the antimicrobial efficacy of a solution according to the present invention using the testing procedures described in Example 5 above. These tests were similar to Example 6 except with a different lot that had been aged for 18 months. The concentration of alexidine was formulated at 4.0 ppm and the time intervals were 15 min, 30 min, 45 min, and 60 min. The results are shown in Table 4 below.
- the alexidine passed the stand alone test at 30 minutes, 45 minutes, and 60 minutes, but only just passed the 15 minute stand-alone test with respect to Serratia marcesens and Candida albicans. It is clear that at 30 min, 45 min, and one hour stand-alone showed greater disinfection, easily passing the acceptance criteria.
- This Example shows the antimicrobial efficacy of a solution according to the present invention using the testing procedures described in Example 5 above. For a final time, these tests were similar to Example 6 except with a different batch.
- the concentration of alexidine was formulated at 4.0 ppm and the time intervals were 15 mn, 30 min, 45 min, and 60 min, which would represent 25%, 50% and 100% of a one hour minimum recommended disinfection period.
- the solution had been aged 19 months at 25° C. The results are shown in Table 5 below.
- the alexidine solution passed the stand-alone test (without rubbing) at 30 minutes, 45 minutes, and 60 minutes, but did not pass the test at 15 minutes, since at 15 minutes the log reduction for Serratia marcesens was less than 3 logs and the number of the yeast Candida albicans was not reduced by at least 1 log.
- Tables 3, 4, and 5 above show some variation due to the testing of different lots of the solutions described in Example 4 above, but that a 4.0 ppm alexidine solution would require at least about 30 minutes in order to pass a stand-alone procedure without rubbing.
- This Example compares the antimicrobial efficacy of a solution according to the present invention in which alexidine is in an excipient of ReNu® MPS solution compared to an analogous solution containing PHMB in ReNu® MPS solution. Both solutions were borate buffered to enhance the efficacy of the biguanide and contained EDTA and Poloxamine surfactant similar to the solution of Example 4.
- ReNu is a registered tradmark of Bausch & Lomb of Rochester, N.Y.
- the testing procedures used for evaluating the antimicrobial efficacy of disinfecting solutions was the same as in Example 5 above. The results are shown in Table 6 below.
- the acceptance criteria was that the number of bacteria recovered per mL must be reduced by a factor of not less than 99.9% (3 logs) with the minimum disinfection period (which would be recommended with the product, in label, package, and/or package insert instructions), and the number of mold and yeast recovered per mL shall be reduced by a factor of not less than 90% (1 log) within the minimum recommended disinfection time, with no increase at four times the minimum recommended disinfection time.
- the above results show that the 1.0 ppm PHMB did not pass the one hour stand-alone test, since the Fusarium solani, a mold, was not sufficiently reduced.
- the 4.0 ppm alexidine solution according to the present invention passed the one hour stand-alone test, showing a reduction in the number of mold by 3.1 log after 1 hour.
- PHMB is used in an amount of about 1.0 ppm in commercial solutions for disinfecting soft lenses. It has been found that increasing the level of PHMB to 3.0 ppm results in clinical findings that suggest PHMB may be less safe than desirable, for use with soft contact lens. In contrast, as shown in the next example, based on rabbit studies, it has been found that a 4.0 ppm solution of alexidine would be very safe for human use in disinfecting soft lenses.
- This example demonstrates the ocular toxicology of alexidine in solutions such as described in Example 4 above, but at various concentrations of the bis(biguanide).
- a series of formulations were prepared in which the amount of alexidine were, respectively 4 ppm (test 1), 6 ppm (test 2), 8 ppm (test 3), 10 ppm (test 4), 12 ppm (test 5), 15 ppm (test 6), 18 ppm (test 7), 22 ppm (test 8), 27 ppm (test 9), 33 ppm (test 10), 40 ppm (test 11) and 50 ppm (test 12).
- These test solutions of alexidine were used in soaking J&J Sure Vue® (etafilcon A) lenses (soft lenses) in 2.5 mL of solution for 1 week or more in order to reach maximal alexidine uptake.
- This example illustrates shows the antimicrobial efficacy of solutions according to the present invention using the testing procedures described in Example 5 above, but specifically to determine the minimal concentration of alexidine to pass the secondary performance criteria, in order to meet the threshold requirements for a regimen involving rubbing of the lens with the solution.
- concentrations of alexidine ranged from 1 ppm to 5 ppm and the time periods tested were 5 minutes and 10 minutes (The one-hour time period is shown in Example 6 above). The results are shown in Table 8 below.
- This example illustrates shows the antimicrobial efficacy of solutions according to the present invention using the testing procedures described in Example 5 above, but specifically to determine the minimal concentration of alexidine to pass the secondary performance criteria, in order to meet the threshold requirements for a regimen involving rubbing the lens with the solution.
- the concentration of alexidine in this set of tests was formulated at 4.0 ppm and the time periods tested were 2.5 minutes, 5 minutes, 7.5 minutes, and 10 minutes, which would represent a 25%, 50%, 75% and 100% testing of the a 10 minute minimum soaking period.
- the solution had been aged for 18 months. The results are shown in Table 9 below.
- results show, although varying between tests (lots), the secondary performance criteria was met in all cases for a minimum soaking period of 10 minutes, and failed in all cases for a minimum soaking period of 2.5 minutes, with some variability in between these two time periods.
- the tests clearly show, however, that the solution satisfies the qualification test for regimen involving rubbing and a soak time of 10 minutes.
- aqueous disinfecting solutions used in the present method comprising a combination of alexidine and polyhexamtheylene biguanide (also referred to as PAPB or PHMB).
- PAPB polyhexamtheylene biguanide
- PHMB polyhexamtheylene biguanide
- the solution is prepared by gradually heating 80 percent of the water to 80° C. while dissolving the disodium EDTA therein.
- the boric acid and sodium borate are added to the heated solution of disodium EDTA and dissolved.
- the sodium chloride is then added to the solution and dissolved, followed by the addition of surfactants.
- the solution is sterilized by autoclaving to 120° C. for 45 minute. After the solution is cooled to room temperature, the bis(biguanide) and PAPB are added through a sterile filter, followed by the balance of distilled water.
- the solution is packaged in sterilized plastic containers.
- This Example illustrates the improved antimicrobial efficacy of a combination of alexidine with PAPB in an aqueous disinfecting solution for contact lenses.
- the testing procedures described in Example 5 above were followed to determine whether the primary performance criteria would be passed at time intervals of 5 min., 15 min, 30 min, and 4 hrs.
- the concentration of alexidine in this set of tests was formulated in amounts ranging from 0.0 to 4.0 ppm in combination with either 0.0 or 0.8 ppm alexidine, the latter the amount of PAPB currently used in commercial multi-purpose solutions for soft contact lenses.
- Table 10 The results are shown in Table 10 below.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Detergent Compositions (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
TABLE 1 ______________________________________ Percent (w/v) ______________________________________ Alexidine.2HCl 0.0004 Poloxamine 1107** 1.0 Na.sub.2 EDTA 0.11 Boric Acid 0.66 Sodium Borate 0.10 Sodium Chloride 0.54 Distilled Water qs 100.0 ______________________________________ **molecular weight 14,500, 70% (w/v) Tetronic ® 1107, a poly(oxypropylene) poly(oxyethylene) block copolymer adduct of ethylene diamine, a trademark of BASF Wyandotte Corp., Wyandotte, MI.
TABLE 2 ______________________________________ Alexidine.2HCl Concentration Log Reduction Microorganism (ppm) (1 hr) ______________________________________ S. aureus 1 1.6 S. aureus 2 4.3 S. aureus 3 >4.8 S. aureus 4 >4.8 S. aureus 5 >4.8 P. aeruginosa 1 >5.0 P. aeruginosa 2 >5.0 P. aeruginosa 3 >5.0 P. aeruginosa 4 >5.0 P. aeruginosa 5 >5.0 S. marcescens 1 3.5 S. marcescens 2 >4.8 S. marcescens 3 >4.8 S. marcescens 4 >4.8 S. marcescens 5 >4.8 ______________________________________
TABLE 3 ______________________________________ Microorganism Soak Period Log Reduction ______________________________________ Staphylococcus 15 min 2.5 aureus 30 min 4.4 45 min >4.9 60 min >4.9 Pseudomonas 15 min 4.0 aeruginosa 30 min >4.8 45 min >4.8 60 min >4.8 Serratia 15 min 3.2 marcescens 30 min >4.7 45 min. >4.7 60 min >4.7 Candida 15 min 1.9 albicans 30 min 2.5 45 min 2.7 60 min 2.8 4 h 3.4 Fusarium 15 min 3.4 solani 30 min 4.3 45 min 4.4 60 min 4.2 4 h >4.4 ______________________________________
TABLE 4 ______________________________________ Microorganism Soak Period Log Reduction ______________________________________ Staphylococcus 15 min 3.7 aureus 30 min 4.7 45 min >4.8 60 min >4.8 Pseudomonas 15 min 4.2 aeruginosa 30 min >4.8 45 min >4.8 60 min >4.8 Serratia 15 min 3.0 marcescens 30 min 4.7 45 min >4.8 60 min >4.8 Candida 15 min 1.0 albicans 30 min 1.7 45 min 1.9 60 min 2.1 4 hrs 3.1 Fusarium 15 min 2.4 solani 30 min >4.5 45 min >4.5 60 min >4.5 4 hrs >4.5 ______________________________________
TABLE 5 ______________________________________ Microorganism Soak Period Log Reduction ______________________________________ Staphylococcus 15 min 3.5 aureus 30 min >4.9 45 min >4.9 60 min >4.9 Pseudomonas 15 min 3.3 aeruginosa 30 min >4.8 45 min >4.8 60 min >4.8 Serratia 15 min 2.5 Marcescens 30 min 4.6 45 min >4.7 60 min >4.7 Candida 15 min 0.9 albicans 30 min 1.7 45 min 1.8 60 min 1.9 4 hrs 2.6 Fusarium 15 min 3.6 solani 30 min >4.6 45 min >4.6 60 min >4.6 4 hrs >4.6 ______________________________________
TABLE 6 ______________________________________ Microorganism Time 1.0 ppm 4.0 ppm Tested Tested PHMB Alexidine · 2HCl ______________________________________ Staphylococcus 1 hr 3.5 >4.9 aureus 2 hr 3.9 >4.9 3 hr >4.9 >4.9 4 hr >4.9 >4.9 Pseudomonas 1 hr 3.5 >4.8 aeruginosa 2 hr 4.0 >4.8 3 hr 4.1 >4.8 4 hr >4.8 >4.8 Serratia 1 hr 3.2 3.7 marcescens 2 hr 4.2 >4.7 3 hr >4.7 >4.7 4 hr >4.7 >4.7 Candida 1 hr 2.9 2.9 albicans 2 hr 3.0 4.3 3 hr 3.4 >4.7 4 hr 3.4 3.9 24 hr 4.3 4.6 Fusarium 1 hr 0.4 3.1 solani 2 hr 0.5 4.1 3 hr 0.4 4.5 4 hr 0.4 4.6 24 hr 1.3 >4.6 ______________________________________
TABLE 7 __________________________________________________________________________ POST LENS APPLICATION ppm Prior to Lens 50-70 7-8 23-24 30-32 Test No. Alexidine.2HCl Application Minutes Hours Hours Hours __________________________________________________________________________ R L R L R L R L R L 1 4 0 0 2 2 2 0 2 0 2 2 2 4 0 0 2 2 2 2 2 2 2 2 3 4 0 0 2 2 2 2 2 2 2 2 4 6 2 0 2 2 2 0 2 0 2 0 5 6 2 2 2 2 2 2 2 2 2 2 6 6 2 2 2 2 2 0 2 0 2 0 7 8 0 0 2 0 2 0 2 2 2 2 8 8 2 2 2 2 2 2 2 0 2 2 9 8 2 2 2 2 2 2 2 2 2 2 10 10 2 0 2 0 4 0 2 0 2 0 11 10 2 2 2 0 2 0 2 2 2 2 12 10 0 0 2 0 4 2 0 0 0 0 13 12 2 0 2 2 2 2 2 2 2 2 14 12 2 2 2 2 2 2 2 2 2 2 15 12 2 2 2 2 2 2 2 2 2 2 16 15 0 0 2 2 4 0 2 0 2 0 17 15 2 2 4 2 4 0 2 2 2 2 18 15 0 0 2 0 4 0 0 0 2 0 19 18 2 0 2 2 6 2 2 0 2 0 20 18 2 2 2 2 6 2 2 2 2 2 21 18 2 2 2 2 6 2 2 2 2 2 22 22 2 0 2 2 11 0 2 0 2 2 23 22 2 2 2 2 11 0 2 0 2 2 24 22 0 0 2 0 11 0 2 0 2 0 25 27 2 0 2 2 13 2 2 2 2 0 26 27 2 0 2 2 11 2 2 2 2 0 27 27 2 2 2 2 6 2 2 2 2 0 28 27 2 0 2 2 11 2 7 2 7 2 29 27 2 0 2 2 11 2 7 2 7 2 30 27 2 0 2 2 9 0 2 0 2 0 __________________________________________________________________________ R = Right (Test) Eye L = Left (Control) Eye
TABLE 8 ______________________________________ Alexidine.2HCL Concentration Log Reduction Log Reduction Microorganism (PPM) at 5 Minutes at 10 Minutes ______________________________________ S. aureus 1.0 0.7 1.0 S. aureus 2.0 1.6 2.6 S. aureus 3.0 2.6 4.0 S. aureus 4.0 4.8 4.8 S. aureus 5.0 4.8 >4.8 P. aeruginosa 1.0 0.5 3.2 P. aeruginosa 2.0 3.0 4.3 P. aeruginosa 3.0 3.8 >5.0 P. aeruginosa 4.0 3.7 >5.0 P. aeruginosa 5.0 >5.0 >5.0 S. marcescens 1.0 0.5 0.7 S. marcescens 2.0 0.8 1.8 S. marcescens 3.0 1.1 2.6 S. marcescens 4.0 2.0 >4.8 S. marcescens 5.0 2.9 >4.8 ______________________________________
TABLE 9 ______________________________________ Soak Period Log Reduction Microorganism (Minutes) Exp. 1 Exp. 2 Exp. 3 ______________________________________ Staphylococcus 2.5 2.2 1.6 2.0 aureus 5.0 2.7 2.0 2.8 7.5 3.1 2.3 3.4 10.0 3.5 2.7 3.9 Pseudomonas 2.5 2.4 1.9 2.7 aeruginosa 5.0 3.2 3.2 3.1 7.5 3.4 3.8 4.1 10.0 >4.8 >4.8 4.9 Serratia 2.5 0.5 0.8 0.8 marcescens 5.0 0.6 2.0 2.0 7.5 0.9 2.8 2.2 10.0 1.2 2.8 2.2 Candida 2.5 0.0 0.1 0.0 albicans 5.0 0.0 0.1 0.0 7.5 0.6 0.5 0.4 10.0 0.7 0.6 0.4 40.0 2.1 1.0 1.0 Fusarium 2.5 2.5 2.5 2.2 solani 5.0 4.3 4.1 2.1 7.5 4.6 4.4 2.4 10.0 >4.6 4.5 2.5 40.0 >4.6 >4.5 >4.6 ______________________________________
______________________________________ Percent (w/v) ______________________________________ PAPB 0.0008 Alexidine.2HCL 0.0002 Poloxamine 1107** 1.0 Na.sub.2 EDTA 0.11 Boric Acid 0.66 Sodium Borate 0.10 Sodium Chloride 0.54 Distilled Water (qs) 100.0 ______________________________________
TABLE 10 ______________________________________ Alexidine.- 2HCl PAPB Log Reduction Log Reduction (ppm) (ppm) Soak Period S. marcescens C. albicans ______________________________________ 0.5 0.8 5 min -- 0.6 15 min 2.0 1.1 30 min 3.2 1.8 60 min 4.3 3.5 1.0 0.8 5 min -- 0.5 15 min 2.6 1.1 30 min 3.7 2.2 60 min >4.3 4.2 2.6 0.8 5 min -- 0.7 15 min 2.7 2.2 30 min >4.3 3.3 60 min >4.3 >4.2 4.0 0.8 5 min -- 1.1 15 min >4.3 3.0 30 min >4.3 >4.2 60 min >4.3 >4.2 0.5 0.0 5 min -- 0.3 15 min 0.6 1.0 30 min 1.6 -0.2 60 min 2.5 -0.1 2.6 0.0 5 min -- 0.4 15 min 2.2 0.5 30 min >4.3 0.5 60 min >4.3 1.4 0.0 0.8 15 min -- 0.6 30 min 1.3 0.8 45 min 2.0 1.4 60 min 3.1 2.9 ______________________________________
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/956,514 US5965088A (en) | 1997-10-23 | 1997-10-23 | Method for providing rapid disinfection of contact lenses |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/956,514 US5965088A (en) | 1997-10-23 | 1997-10-23 | Method for providing rapid disinfection of contact lenses |
Publications (1)
Publication Number | Publication Date |
---|---|
US5965088A true US5965088A (en) | 1999-10-12 |
Family
ID=25498320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/956,514 Expired - Lifetime US5965088A (en) | 1997-10-23 | 1997-10-23 | Method for providing rapid disinfection of contact lenses |
Country Status (1)
Country | Link |
---|---|
US (1) | US5965088A (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020141899A1 (en) * | 2000-09-28 | 2002-10-03 | Fu-Pao Tsao | Compositions and methods for cleaning contact lenses |
US6478881B2 (en) * | 1999-05-12 | 2002-11-12 | Vista Scientific L.L.C. | Contact lens cleaning solution |
US20030119684A1 (en) * | 2001-11-21 | 2003-06-26 | Fu-Pao Tsao | Conditioning solution for contact lenses and a method of using the same |
US6762162B1 (en) | 2003-06-18 | 2004-07-13 | S. C. Johnson & Son, Inc. | Disinfecting cationic polymer cleaner comprising an acrylate cationic polymer |
WO2004112848A1 (en) * | 2003-06-16 | 2004-12-29 | Bausch & Lomb Incorporated | Lens care solutions for hydrogel contact lenses |
US20050136029A1 (en) * | 2003-12-19 | 2005-06-23 | Alcon, Inc. | Alkylpolypropyleneoxide amidotriamines and method of using same |
US20060197067A1 (en) * | 2005-03-04 | 2006-09-07 | Erning Xia | Radiation-absorbing materials, ophthalmic compositions containing same, and method of treating ophthalmic devices |
US20060275349A1 (en) * | 1999-05-21 | 2006-12-07 | 3M Innovative Properties Company | Coated antimicrobial articles |
US20060276541A1 (en) * | 1999-11-24 | 2006-12-07 | 3M Innovative Properties Company | Fruit, vegetable, and seed disinfectants |
WO2006068899A3 (en) * | 2004-12-22 | 2007-01-25 | Bausch & Lomb | Preserved ophthalmic compositions comprising aloe vera |
US20070140897A1 (en) * | 2005-12-21 | 2007-06-21 | Hongna Wang | Ph stable biguanide composition and method of treatment and prevention of infections |
US20070142478A1 (en) * | 2005-12-21 | 2007-06-21 | Erning Xia | Combination antimicrobial composition and method of use |
US20070142321A1 (en) * | 2005-12-21 | 2007-06-21 | Roya Borazjani | Method for preventing growth of bacteria on contact lenses with eye drops |
WO2008051733A3 (en) * | 2006-10-23 | 2008-07-31 | Bausch & Lomb | Biguanide composition with low terminal amine |
US20080311070A1 (en) * | 2007-06-13 | 2008-12-18 | Burke Susan E | Ophthalmic composition with hyaluronic acid |
US20100282409A1 (en) * | 2007-12-31 | 2010-11-11 | 3M Innovative Properties Company | Antimicrobial compositions |
WO2011139569A1 (en) * | 2010-04-26 | 2011-11-10 | Bausch & Lomb Incorporated | Ophthalmic compositions with biguanide and peg-glycerol esters |
CN102993057A (en) * | 2012-12-04 | 2013-03-27 | 甘肃省化工研究院 | Synthesis method of 1,6-bis(cyano-guanidino) hexane |
US8476319B2 (en) | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
US8512723B2 (en) | 2003-09-09 | 2013-08-20 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US8522277B2 (en) | 1998-07-23 | 2013-08-27 | Comcast Ip Holdings I, Llc | Interactive user interface |
US8661465B2 (en) | 1999-10-27 | 2014-02-25 | Comcast Ip Holdings I, Llc | Apparatus and method for combining realtime and non-realtime encoded content |
US8930998B2 (en) | 1999-10-27 | 2015-01-06 | Comcast Ip Holdings I, Llc | Method and system for providing a program guide and multiple video streams using slice-based encoding |
US9154813B2 (en) | 2011-06-09 | 2015-10-06 | Comcast Cable Communications, Llc | Multiple video content in a composite video stream |
US9286294B2 (en) | 1992-12-09 | 2016-03-15 | Comcast Ip Holdings I, Llc | Video and digital multimedia aggregator content suggestion engine |
US9456241B2 (en) | 1999-04-15 | 2016-09-27 | Comcast Ip Holdings I, Llc | Server-centric customized interactive program guide in an interactive television environment |
US9674586B2 (en) | 1998-07-23 | 2017-06-06 | Comcast Ip Holdings I, Llc | Data structure and methods for providing an interactive program guide |
US9813641B2 (en) | 2000-06-19 | 2017-11-07 | Comcast Ip Holdings I, Llc | Method and apparatus for targeting of interactive virtual objects |
US9826770B2 (en) | 2005-03-10 | 2017-11-28 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
US9924234B2 (en) | 1998-07-23 | 2018-03-20 | Comcast Ip Holdings I, Llc | Data structure and methods for providing an interactive program |
US10140433B2 (en) | 2001-08-03 | 2018-11-27 | Comcast Ip Holdings I, Llc | Video and digital multimedia aggregator |
US10349096B2 (en) | 2001-08-03 | 2019-07-09 | Comcast Ip Holdings I, Llc | Video and digital multimedia aggregator content coding and formatting |
US10918618B2 (en) | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1095902A (en) * | 1964-04-09 | 1967-12-20 | Sterling Drug Inc | Guanidine derivatives |
US3428567A (en) * | 1965-11-03 | 1969-02-18 | Dow Chemical Co | Stabilizer for polyols |
GB1432345A (en) * | 1972-04-13 | 1976-04-14 | Smith Enphew Research Ltd | Ophthalmic compositions and contact lens disinfecting compo sitions |
US4354952A (en) * | 1981-03-12 | 1982-10-19 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution comprising chlorhexidine and salts thereof |
US4361548A (en) * | 1980-11-28 | 1982-11-30 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution (polymeric) |
FR2517208A1 (en) * | 1981-12-02 | 1983-06-03 | Pos Lab | Poly:hexa:methylene biguanide polymer contg. compsn. - for cleaning and sterilising auricular and ocular prosthesis e.g. contact lenses |
EP0125092A1 (en) * | 1983-05-09 | 1984-11-14 | Imperial Chemical Industries Plc | Bisbiguanide compounds |
US4758595A (en) * | 1984-12-11 | 1988-07-19 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
WO1992011876A1 (en) * | 1990-12-27 | 1992-07-23 | Schering Corporation | Method and composition for disinfecting contact lenses |
EP0575290A1 (en) * | 1992-06-17 | 1993-12-22 | Ciba-Geigy Ag | Product for care of hard or soft contact lenses |
WO1994019027A1 (en) * | 1993-02-26 | 1994-09-01 | Wesley-Jessen Corporation | Method and composition for disinfecting contact lenses |
EP0384666B1 (en) * | 1989-02-21 | 1994-11-09 | BAUSCH & LOMB INCORPORATED | Method and composition for cleaning and disinfecting contact lenses |
US5411598A (en) * | 1989-01-31 | 1995-05-02 | Ciba-Geigy Corporation | Rapid method for cleaning/disinfecting ophthalmic devices using novel glycol/lower alkanol solution |
US5411597A (en) * | 1989-01-31 | 1995-05-02 | Ciba-Geigy Corporation | Rapid ophthalmic disinfection method and solution using salt and glycol and/or lower alkanol |
-
1997
- 1997-10-23 US US08/956,514 patent/US5965088A/en not_active Expired - Lifetime
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1095902A (en) * | 1964-04-09 | 1967-12-20 | Sterling Drug Inc | Guanidine derivatives |
US3428567A (en) * | 1965-11-03 | 1969-02-18 | Dow Chemical Co | Stabilizer for polyols |
GB1432345A (en) * | 1972-04-13 | 1976-04-14 | Smith Enphew Research Ltd | Ophthalmic compositions and contact lens disinfecting compo sitions |
US4361548A (en) * | 1980-11-28 | 1982-11-30 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution (polymeric) |
US4354952A (en) * | 1981-03-12 | 1982-10-19 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution comprising chlorhexidine and salts thereof |
FR2517208A1 (en) * | 1981-12-02 | 1983-06-03 | Pos Lab | Poly:hexa:methylene biguanide polymer contg. compsn. - for cleaning and sterilising auricular and ocular prosthesis e.g. contact lenses |
EP0125092A1 (en) * | 1983-05-09 | 1984-11-14 | Imperial Chemical Industries Plc | Bisbiguanide compounds |
US4758595A (en) * | 1984-12-11 | 1988-07-19 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US5411598A (en) * | 1989-01-31 | 1995-05-02 | Ciba-Geigy Corporation | Rapid method for cleaning/disinfecting ophthalmic devices using novel glycol/lower alkanol solution |
US5411597A (en) * | 1989-01-31 | 1995-05-02 | Ciba-Geigy Corporation | Rapid ophthalmic disinfection method and solution using salt and glycol and/or lower alkanol |
EP0384666B1 (en) * | 1989-02-21 | 1994-11-09 | BAUSCH & LOMB INCORPORATED | Method and composition for cleaning and disinfecting contact lenses |
WO1992011876A1 (en) * | 1990-12-27 | 1992-07-23 | Schering Corporation | Method and composition for disinfecting contact lenses |
EP0575290A1 (en) * | 1992-06-17 | 1993-12-22 | Ciba-Geigy Ag | Product for care of hard or soft contact lenses |
WO1994019027A1 (en) * | 1993-02-26 | 1994-09-01 | Wesley-Jessen Corporation | Method and composition for disinfecting contact lenses |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9286294B2 (en) | 1992-12-09 | 2016-03-15 | Comcast Ip Holdings I, Llc | Video and digital multimedia aggregator content suggestion engine |
US9674586B2 (en) | 1998-07-23 | 2017-06-06 | Comcast Ip Holdings I, Llc | Data structure and methods for providing an interactive program guide |
US9924234B2 (en) | 1998-07-23 | 2018-03-20 | Comcast Ip Holdings I, Llc | Data structure and methods for providing an interactive program |
US8522277B2 (en) | 1998-07-23 | 2013-08-27 | Comcast Ip Holdings I, Llc | Interactive user interface |
US9456241B2 (en) | 1999-04-15 | 2016-09-27 | Comcast Ip Holdings I, Llc | Server-centric customized interactive program guide in an interactive television environment |
US6478881B2 (en) * | 1999-05-12 | 2002-11-12 | Vista Scientific L.L.C. | Contact lens cleaning solution |
US20060275349A1 (en) * | 1999-05-21 | 2006-12-07 | 3M Innovative Properties Company | Coated antimicrobial articles |
US8930998B2 (en) | 1999-10-27 | 2015-01-06 | Comcast Ip Holdings I, Llc | Method and system for providing a program guide and multiple video streams using slice-based encoding |
US9264711B2 (en) | 1999-10-27 | 2016-02-16 | Comcast Ip Holdings I, Llc | Apparatus and method for combining realtime and non-realtime encoded content |
US8661465B2 (en) | 1999-10-27 | 2014-02-25 | Comcast Ip Holdings I, Llc | Apparatus and method for combining realtime and non-realtime encoded content |
US20060276541A1 (en) * | 1999-11-24 | 2006-12-07 | 3M Innovative Properties Company | Fruit, vegetable, and seed disinfectants |
US9813641B2 (en) | 2000-06-19 | 2017-11-07 | Comcast Ip Holdings I, Llc | Method and apparatus for targeting of interactive virtual objects |
US20020141899A1 (en) * | 2000-09-28 | 2002-10-03 | Fu-Pao Tsao | Compositions and methods for cleaning contact lenses |
US7022654B2 (en) | 2000-09-28 | 2006-04-04 | Novartis Ag | Compositions and methods for cleaning contact lenses |
US10349096B2 (en) | 2001-08-03 | 2019-07-09 | Comcast Ip Holdings I, Llc | Video and digital multimedia aggregator content coding and formatting |
US10140433B2 (en) | 2001-08-03 | 2018-11-27 | Comcast Ip Holdings I, Llc | Video and digital multimedia aggregator |
US20030119684A1 (en) * | 2001-11-21 | 2003-06-26 | Fu-Pao Tsao | Conditioning solution for contact lenses and a method of using the same |
WO2004112848A1 (en) * | 2003-06-16 | 2004-12-29 | Bausch & Lomb Incorporated | Lens care solutions for hydrogel contact lenses |
US6762162B1 (en) | 2003-06-18 | 2004-07-13 | S. C. Johnson & Son, Inc. | Disinfecting cationic polymer cleaner comprising an acrylate cationic polymer |
US10471036B2 (en) | 2003-09-09 | 2019-11-12 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US8512723B2 (en) | 2003-09-09 | 2013-08-20 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US6962693B2 (en) * | 2003-12-19 | 2005-11-08 | Alcon, Inc. | Alkylpolypropyleneoxide amidotriamines and method of using same |
US20050136029A1 (en) * | 2003-12-19 | 2005-06-23 | Alcon, Inc. | Alkylpolypropyleneoxide amidotriamines and method of using same |
WO2006068899A3 (en) * | 2004-12-22 | 2007-01-25 | Bausch & Lomb | Preserved ophthalmic compositions comprising aloe vera |
US20060197067A1 (en) * | 2005-03-04 | 2006-09-07 | Erning Xia | Radiation-absorbing materials, ophthalmic compositions containing same, and method of treating ophthalmic devices |
WO2006096422A1 (en) * | 2005-03-04 | 2006-09-14 | Bausch & Lomb Incorporated | Radiation-absorbing materials, ophthalmic compositions containing same, and method of treating ophthalmic devices |
US8476319B2 (en) | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
US9826770B2 (en) | 2005-03-10 | 2017-11-28 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
US10918618B2 (en) | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
US20070142321A1 (en) * | 2005-12-21 | 2007-06-21 | Roya Borazjani | Method for preventing growth of bacteria on contact lenses with eye drops |
US20070142478A1 (en) * | 2005-12-21 | 2007-06-21 | Erning Xia | Combination antimicrobial composition and method of use |
US20070140897A1 (en) * | 2005-12-21 | 2007-06-21 | Hongna Wang | Ph stable biguanide composition and method of treatment and prevention of infections |
KR101487218B1 (en) * | 2006-10-23 | 2015-01-28 | 아치 캐미컬스, 인크. | Biguanide composition with low terminal amine |
US7897553B2 (en) | 2006-10-23 | 2011-03-01 | Bausch & Lomb Incorporated | Biguanide composition with low terminal amine |
WO2008051733A3 (en) * | 2006-10-23 | 2008-07-31 | Bausch & Lomb | Biguanide composition with low terminal amine |
CN101594779B (en) * | 2006-10-23 | 2015-12-02 | 阿奇化工公司 | Biguanide compositions with fewer terminal amine groups |
US20080261841A1 (en) * | 2006-10-23 | 2008-10-23 | Heiler David J | Biguanide composition with low terminal amine |
US20080311070A1 (en) * | 2007-06-13 | 2008-12-18 | Burke Susan E | Ophthalmic composition with hyaluronic acid |
US8623935B2 (en) | 2007-12-31 | 2014-01-07 | 3M Innovative Properties Company | Antimicrobial compositions |
US20100282409A1 (en) * | 2007-12-31 | 2010-11-11 | 3M Innovative Properties Company | Antimicrobial compositions |
US8501200B2 (en) | 2010-04-26 | 2013-08-06 | Bausch & Lomb Incorporated | Ophthalmic compositions with biguanide and PEG-glycerol esters |
WO2011139569A1 (en) * | 2010-04-26 | 2011-11-10 | Bausch & Lomb Incorporated | Ophthalmic compositions with biguanide and peg-glycerol esters |
US8889160B2 (en) | 2010-04-26 | 2014-11-18 | Bausch & Lomb Incorporated | Ophthalmic compositions with biguanide and PEG-glycerol esters |
EP2664665A1 (en) * | 2010-04-26 | 2013-11-20 | Bausch & Lomb Incorporated | Ophthalmic compositions with biguanide and PEG-glycerol esters |
US9154813B2 (en) | 2011-06-09 | 2015-10-06 | Comcast Cable Communications, Llc | Multiple video content in a composite video stream |
CN102993057A (en) * | 2012-12-04 | 2013-03-27 | 甘肃省化工研究院 | Synthesis method of 1,6-bis(cyano-guanidino) hexane |
CN102993057B (en) * | 2012-12-04 | 2014-09-17 | 甘肃省化工研究院 | Synthesis method of 1,6-bis(cyano-guanidino) hexane |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5965088A (en) | Method for providing rapid disinfection of contact lenses | |
US6153568A (en) | Compositions comprising polyquaterniums in combination with polymeric biguanides for disinfecting contact lenses | |
US6309658B1 (en) | Treatment of contact lenses with aqueous solution comprising a carbonate salt for enhanced cleaning | |
US6143244A (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant and a complementary phosphate-borate buffer system | |
US6369112B1 (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol | |
US6309596B1 (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine | |
WO1998020738A1 (en) | Compositions and methods in which bis(biguanides) provide enhanced antimicrobial efficacy for disinfecting contact lenses | |
EP0938344B1 (en) | Method for providing rapid disinfection of contact lenses | |
EP1030902A1 (en) | Disinfecting contact lenses with bis(biguanides) and polymeric biguanides | |
AU739900B2 (en) | Disinfecting contact lenses with bis(biguanides) and polymeric biguanides | |
HK1024426B (en) | Method for providing rapid disinfection of contact lenses | |
MXPA00004564A (en) | Disinfecting contact lenses with bis(biguanides) and polymeric biguanides | |
HK1031343B (en) | Treatment of contact lenses with aqueous solution comprising an alkali carbonate | |
MXPA00004566A (en) | Disinfecting contact lenses with polyquaterniums and polymeric biguanides | |
HK1042857B (en) | Contact lens cleaner comprising biguanide, tyloxapol, and poloxamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAUSCH & LOMB INCORPORATED, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEVER, ANDREA M.;LEVER, O. WILLIAM;REEL/FRAME:008791/0894 Effective date: 19961113 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: CREDIT SUISSE, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNORS:BAUSCH & LOMB INCORPORATED;WP PRISM INC.;B&L CRL INC.;AND OTHERS;REEL/FRAME:020733/0765 Effective date: 20080320 Owner name: CREDIT SUISSE,NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNORS:BAUSCH & LOMB INCORPORATED;WP PRISM INC.;B&L CRL INC.;AND OTHERS;REEL/FRAME:020733/0765 Effective date: 20080320 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: BAUSCH & LOMB INCORPORATED, NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH;REEL/FRAME:028726/0142 Effective date: 20120518 |
|
AS | Assignment |
Owner name: CITIBANK N.A., AS ADMINISTRATIVE AGENT, DELAWARE Free format text: SECURITY AGREEMENT;ASSIGNORS:BAUSCH & LOMB INCORPORATED;EYEONICS, INC.;REEL/FRAME:028728/0645 Effective date: 20120518 |
|
AS | Assignment |
Owner name: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.), NEW YORK Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:CITIBANK N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:030995/0444 Effective date: 20130805 Owner name: BAUSCH & LOMB INCORPORATED, NEW YORK Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:CITIBANK N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:030995/0444 Effective date: 20130805 Owner name: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.), Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:CITIBANK N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:030995/0444 Effective date: 20130805 Owner name: ISTA PHARMACEUTICALS, NEW YORK Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:CITIBANK N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:030995/0444 Effective date: 20130805 |
|
AS | Assignment |
Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:BAUSCH & LOMB INCORPORATED;REEL/FRAME:031156/0508 Effective date: 20130830 Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL Free format text: SECURITY AGREEMENT;ASSIGNOR:BAUSCH & LOMB INCORPORATED;REEL/FRAME:031156/0508 Effective date: 20130830 |
|
AS | Assignment |
Owner name: BARCLAYS BANK PLC, AS SUCCESSOR AGENT, NEW YORK Free format text: NOTICE OF SUCCESSION OF AGENCY;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS, LLC;REEL/FRAME:034749/0689 Effective date: 20150108 |
|
AS | Assignment |
Owner name: THE BANK OF NEW YORK MELLON, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:BAUSCH & LOMB INCORPORATED;REEL/FRAME:043251/0932 Effective date: 20170717 |
|
AS | Assignment |
Owner name: UNIVERSITY OF ROCHESTER, NEW YORK Free format text: RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689);ASSIGNOR:BARCLAYS BANK PLC;REEL/FRAME:061778/0146 Effective date: 20221019 Owner name: BAUSCH & LOMB INCORPORATED, NEW YORK Free format text: RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689);ASSIGNOR:BARCLAYS BANK PLC;REEL/FRAME:061778/0146 Effective date: 20221019 |
|
AS | Assignment |
Owner name: 1530065 B.C. LTD., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: 1261229 B.C. LTD., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: VRX HOLDCO LLC, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: V-BAC HOLDING CORP., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: SOLTA MEDICAL DUTCH HOLDINGS B.V., NETHERLANDS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.), POLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: ORAPHARMA, INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.), POLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH US, LLC, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA), POLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC), HUNGARY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH HOLDCO LIMITED, IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH COMPANIES INC., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH AMERICAS, INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH+LOMB OPS B.V., NETHERLANDS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH & LOMB MEXICO, S.A. DE C.V., MEXICO Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: SOLTA MEDICAL IRELAND LIMITED, IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: HUMAX PHARMACEUTICAL S.A., COLOMBIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: MEDICIS PHARMACEUTICAL CORPORATION, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: SANTARUS, INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: SALIX PHARMACEUTICALS, LTD, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: SALIX PHARMACEUTICALS, INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED), IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: PRECISION DERMATOLOGY, INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 Owner name: SOLTA MEDICAL, INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199 Effective date: 20250408 |